S.No. Age Sex CAG Therapies (pre / post) 1. 71 M 0VD D&E/D&E 2. 52  F 1VD D&E/A300 mg 3. 60 M 2VD D&E/P 0.6 g 4. 58  M 0VD D&E/SU (GLIBENCRAMIDE 5 mg/day) 5. 60  M 0VD D&E/A 300 g 6. 68  M 1VD SU (GLICRARISIDE 80 mg/day)/In (NOVOLIN 30R (10-0-10) 7. 55 M 0VD D&E/D&E 8. 56 M 0VD SU (GLIBENCRAMIDE 5mg/day)/In (NOVOLIN R (8-6-6) 9. 64 F 2VD D&E/A 300 mg 10. 62 F 1VD D&E/D&E 11. 68 M 0VD SU (GLIBENCRAMIDE 2.5 mg/day)/SU (GLIBENCRAMIDE 2.5 mg/day) 12. 56 M 0VD SU (GLIMEPIRID 3 mg/day)/In (NOVOLIN R (10-10-10) 13. 69 M 1VD In (NOVOLIN 30R (14-0-14)/In (NOVOLIN 30R (14-0-14) 14. 57 M 0VD In (NOVORAPID 30R (18-0-12)/In (NOVORAPID 30R (18-0-12) 15. 66 F 2VD A 300 mg/A300 mg 16. 64 F 2VD In (NOVOLIN 30R (14-0-14)/In (NOVOLIN 30R (14-0-14)) +TRO 200 mg 17. 64 M 0VD D&E/D&E 18.  51 M 0VD D&E/D&E+P 0.6 g 19. 69 M 1VD  In (NOVOLIN 30R (8-0-8))/In (NOVOLIN 30R (8-0-8)) + D&E 20.  65 M 0VD D&E/TRO 200 mg 21. 59  M 1VD D&E/D&E 22. 64 M 2VD D&E/D&E+SU (GLIMEPIRID mg/day) 23. 63 M 0VD D&E/D&E 24. 68 F 0VD SU (GLICRARISIDE 80 mg/day)/SU (GLICRARISIDE 80 mg/day +TRO 200 mg) 25. 55  M 2VD SU (GLIMEPIRID 2 mg/day)/SU (GLIMEPIRID 2 mg/day) 26. 65 M 0VD D&E/D&E 27. 56 M 0VD SU (GLIMEPIRID 2 mg/day)/SU (GLIMEPIRID 2 mg/day) 28. 66 M 1VD SU (GLIBENCRAMIDE 2.5 mg/day)/SU (GLIBENCRAMIDE2.5 mg/day )+TRO 200 mg 29. 64 M 0VD D&E/TRO 200 mg 30. 48 F 0VD D&E/D&E 31. 64 M 1VD D&E/TRO 200 mg 32. 72 F 0VD D&E/D&E 33. 60 M 0VD D&E/D&E 34. 66 M 0VD D&E/In (NOVOLIN R (8-6-6) MFR: Myocardial Flow Reserve; CAG: Coronary Angiography Findings; 0VD: 0 Vessel Disease; 1VD: 1 Vessel Disease; 2VD: 2 Vessel Disease; D: Diet Therapy; E: Exercise Therapy; SU: Sulfonylurea Drugs; A: Acarbose; P: Poglybose; TRO: Troglytazone; In: Insulin

Table 3: Data on MFR, glycemic control, and therapy in patients with T2DM who underwent PET perfusion studies.